Molecular profiling of BRAF-V600E-mutant metastatic intestines cancer cells in the phaseu00e2 $ 3 GUIDEPOST CRC test

.Competing interests.S.K.: Supply as well as Various Other Possession Enthusiasms: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Role: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Health And Wellness, Bicara Therapeutics, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Undertaking BioMedicines, Flame Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapy, Servier, Xilis. Research Study Financing: Amgen (Inst), Selection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst).

D.A.M.: Job: Formerly Pfizer. Supply and also Other Ownership Interests: Pfizer. J.P.: Job: Formerly Pfizer.

Supply as well as Other Possession Stakes: Pfizer. F.C.: Consulting or even Advisory Part: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst).

J.D.: Consulting or Advisory Duty: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Analysis Backing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Role: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo.

H.S.W.: Consulting or even Advisory Part: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Rehabs, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Research Study Financing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Drug, Sumitomo Corp., Takeda.

Research Study Financing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Employment: Pfizer.

Stock and Other Possession Stakes: Pfizer. X.Z.: Employment: Pfizer. Stock as well as Other Possession Interests: Pfizer.

Patents, Royalties, Other Patent: Johns Hopkins Educational Institution. P.H.: Job: Pfizer. Supply and also Various Other Ownership Interests: Pfizer.

T.X.: Work: Pfizer. Inventory and Various Other Ownership Interests: Pfizer. R.Y.: Consulting or Advisory Job: Array BioPharma/Pfizer, Mirati Therapies, Zai Lab, Amgen.

Research Backing: Array BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapeutics (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Function: Selection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Therapeutics, TheraMyc.

Other Partnership: Amgen, Variety Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health And Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Institute for Medical Education, Pfizer, PharmaMar, Physicansu00e2 $ Learning Information, Sanofi-Aventis, Servier, Taiho Pharmaceutical.